FDA has published and notified registrants of facility fees for the Over-the-Counter Monograph Drug User Program. Distilleries throughout the US have received these notices, as any distillery who produced hand sanitizer under the Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance, was directed to register. Although ACSA recognizes FDA was authorized to execute funding measures, until this notice and publication in the Federal Register, FDA was silent on the issue.
ACSA is communicating directly with the FDA to determine under what circumstances the fees are applicable. Moreover, we are taking all steps to advocate for a waiver for those distilleries who produced hand sanitizer on a temporary basis and have no plans to continue to manufacture and sell into 2021.